Celldex Therapeutics (NASDAQ:CLDX) Shares Up 2.7%

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) traded up 2.7% during mid-day trading on Wednesday . The stock traded as high as $39.81 and last traded at $39.66. 202,977 shares traded hands during mid-day trading, a decline of 77% from the average session volume of 896,324 shares. The stock had previously closed at $38.60.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on CLDX shares. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a research report on Friday, March 22nd. HC Wainwright reaffirmed a "buy" rating and set a $80.00 price target on shares of Celldex Therapeutics in a report on Wednesday. Guggenheim lifted their price objective on Celldex Therapeutics from $72.00 to $90.00 and gave the stock a "buy" rating in a report on Tuesday, February 27th. Finally, TD Cowen began coverage on shares of Celldex Therapeutics in a research note on Wednesday, December 20th. They set an "outperform" rating on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $66.00.

Celldex Therapeutics Stock Up 2.7 %

The company has a market cap of $2.22 billion, a P/E ratio of -13.58 and a beta of 1.49. The company has a fifty day moving average of $41.98 and a 200 day moving average of $35.68.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last released its quarterly earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.76) by $0.19. Celldex Therapeutics had a negative return on equity of 41.06% and a negative net margin of 2,054.46%. The business had revenue of $4.13 million during the quarter, compared to the consensus estimate of $1.20 million. As a group, research analysts forecast that Celldex Therapeutics, Inc. will post -2.85 EPS for the current year.

Institutional Investors Weigh In On Celldex Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Wellington Management Group LLP increased its stake in shares of Celldex Therapeutics by 19.2% in the fourth quarter. Wellington Management Group LLP now owns 6,476,561 shares of the biopharmaceutical company's stock worth $256,860,000 after purchasing an additional 1,044,728 shares in the last quarter. Eventide Asset Management LLC increased its stake in Celldex Therapeutics by 126.9% in the 4th quarter. Eventide Asset Management LLC now owns 3,630,013 shares of the biopharmaceutical company's stock worth $143,966,000 after buying an additional 2,030,013 shares in the last quarter. BlackRock Inc. raised its holdings in Celldex Therapeutics by 0.8% during the first quarter. BlackRock Inc. now owns 3,250,638 shares of the biopharmaceutical company's stock valued at $116,958,000 after acquiring an additional 25,922 shares during the period. State Street Corp boosted its stake in shares of Celldex Therapeutics by 20.4% in the second quarter. State Street Corp now owns 3,228,852 shares of the biopharmaceutical company's stock worth $87,050,000 after acquiring an additional 546,124 shares during the period. Finally, Kynam Capital Management LP grew its position in shares of Celldex Therapeutics by 23.1% during the third quarter. Kynam Capital Management LP now owns 3,200,000 shares of the biopharmaceutical company's stock worth $88,064,000 after purchasing an additional 600,000 shares in the last quarter.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.